https://www.nature.com/articles/d41586-023-03969-5 Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 20 December 2023 Cancer-fighting CAR-T cells could be made inside body with viral injection Scientists are devising ways to edit the genomes of immune cells without having to extract them from those being treated. By * Heidi Ledford 1. Heidi Ledford View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email Coloured scanning electron micrograph of a breast cancer cell (green) being attacked by a chimeric antigen receptor T-cell (orange). A breast cancer cell (green; artificially coloured) is attacked by a CAR T cell (orange).Credit: Eye of Science/Science Photo Library Researchers are closing in on ways to produce CAR T cells in the body, raising hopes that the notoriously expensive and bespoke cancer therapies might one day become more accessible. In CAR-T treatment, immune cells called T cells are removed from the person receiving treatment, engineered to target cancer cells and reintroduced to their body. The process has yielded dramatic recoveries from advanced forms of some blood cancers, but its high price and technical difficulty have placed it out of reach for many people. Results presented at the American Society of Hematology annual meeting in San Diego, California on 11 December suggest that people undergoing treatment might eventually just get an injection of a virus that infects T cells. The virus would then insert the genes needed to guide the T cells to tumour cells. "You don't need to take the cells out, you don't need to purify them," says John DiPersio, a transplant immunologist and oncologist at Washington University in St. Louis, Missouri, who says that he was sceptical that the approach would work until he heard the talks at the meeting. "They convinced me that it's possible." Precision targeting The key lies in finding ways to genetically engineer T cells to express chimeric antigen receptors (CARs), proteins that recognize cancer -- without meddling with the genomes of other cells, says Els Verhoeyen, an INSERM research director at the International Center for Infectious Disease Research in Lyon, France, who develops viruses for use in gene therapies. To do so, she and other researchers have been modifying viruses to recognize molecules found only on the surface of T cells. [d41586-023] 'It's all gone': CAR-T therapy forces autoimmune diseases into remission At the haematology conference, two companies presented the results of their efforts to use viruses to engineer T cells still inside the bodies of monkeys. Teams from both Interius BioTherapeutics in Philadelphia, Pennsylvania and Umoja Biopharma in Seattle, Washington, generated CAR-T treatments that target other immune cells called B cells, mimicking the action of approved CAR-T therapies that treat cancers caused by abnormal B cells. In both companies' experiments, the treatment was sufficient to deplete the monkeys' B cells. Interius reported that B-cell counts were reduced by at least 75% in 15 out of 16 animals treated. The two companies plan to request authorization next year from the US Food and Drug Administration to begin trials on people. "The goal now really is kind of within reach," said Stephen Russell, the chief executive of Vyriad, a biotechnology company in Rochester, Minnesota, who presented similar results on mice at the meeting. Ready made cells For DiPersio, the monkey results were a particular surprise. T cells tend to be in an inactive state as they circulate in the bloodstream, which makes them less likely to be infected by the viruses used to shuttle in the genes. As a result, DiPersio says that he had not expected that enough T cells would be engineered to produce such dramatic reductions in B-cell numbers. "You just inject a virus that has all of these targeting molecules on it and that does the trick," he says. The hope is that the technique could expand the use of CAR-T therapies: the current cost of the treatment and necessary hospital care can together exceed half a million US dollars. [d41586-023] Could CAR-T-cell therapy offer hope to children with cancer? A host of challenges awaits that approach as well, however. For one, regulators will want to see evidence that the process truly targets only T cells and leaves other cells untouched, says Verheoyen. Researchers have also tried to generate CAR T cells from cells that have been donated by an unrelated person, and engineered to evade detection by the recipient's immune system. If successful, that would allow cells from a single donor to be used to treat many people. That approach still holds promise, but the results from these therapies have thus far been disappointing, driving greater interest in approaches that can generate CAR-T cells directly in the body, says Andrew Scharenberg, chief executive of Umoja. Less than a block away from Umoja, near the eastern shore of Lake Union in Seattle, sits Sana Biotechnology, a company that has been developing a virus designed by Verhoeyen to generate CAR T cells in the body. Earlier this year, Sana announced that it was scaling back that programme to concentrate on other projects, including CAR-T therapies made from donor cells. It was a difficult decision, says Steve Harr, chief executive of the company. But the other programmes were further along, whereas "there's a lot of scientific work to do," to sort out the logistics of commercializing a CAR-T therapy made in the body, he says. "There was more risk," to inside-the-body CAR-T, he says. "But I still like it. We'll do it over time." doi: https://doi.org/10.1038/d41586-023-03969-5 Reprints and permissions Related Articles * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] Building better CAR-T therapies * [d41586-023] The race to supercharge cancer-fighting T cells * [d41586-023] CRISPR cancer trial success paves the way for personalized treatments * [d41586-023] Cancer treatments boosted by immune-cell hacking Subjects * Immunology * Medical research * Biotechnology Latest on: Immunology Contact-tracing app predicts risk of SARS-CoV-2 transmission Contact-tracing app predicts risk of SARS-CoV-2 transmission News & Views 21 DEC 23 Vaccines reduce the risk of long COVID in children Vaccines reduce the risk of long COVID in children News 20 DEC 23 How Dark Souls and Darth Revan helped me to make sense of my professorship How Dark Souls and Darth Revan helped me to make sense of my professorship Career Column 19 DEC 23 Medical research Scientists question cancer tests that use microscopic nematode worms Scientists question cancer tests that use microscopic nematode worms News 20 DEC 23 The cancer physician who helped to deliver a life-extending treatment The cancer physician who helped to deliver a life-extending treatment News Feature 13 DEC 23 Weight-loss-drug pioneer: this biochemist finally gained recognition for her work Weight-loss-drug pioneer: this biochemist finally gained recognition for her work News Feature 13 DEC 23 Biotechnology Modeling post-implantation human development to yolk sac blood emergence Article 13 DEC 23 Australian Indigenous genomes are highly diverse and unlike those anywhere else Australian Indigenous genomes are highly diverse and unlike those anywhere else News 13 DEC 23 The landscape of genomic structural variation in Indigenous Australians The landscape of genomic structural variation in Indigenous Australians Article 13 DEC 23 Nature Careers Jobs * Professor/Associate Professor/Assistant Professor/Senior Lecturer /Lecturer The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) [] * Professor/Associate Professor/Assistant Professor/Senior Lecturer /Lecturer The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) [] * Faculty Positions in Multiscale Research Institute for Complex Systems, Fudan University The Multiscale Research Institute for Complex Systems (MRICS) at Fudan University is located at the Zhangjiang Campus of Fudan University. Shanghai, China Fudan University [] * Tumor Microenvironment in Metastasis Postdoctoral Fellow Oskarsson lab studies the molecular interactions between cancer cells and the microenvironment in metastasis and in response to therapeutic interventi Tampa, Florida H. Lee Moffitt Cancer Center & Research Institute [] * Cancer Biology Postdoctoral Fellow The Jiang Lab (https://lab.moffitt.org/jiang/ ) in the Dept. of Molecular Oncology-Moffitt Cancer Center is now recruiting postdoctoral fellows. Tampa, Florida H. Lee Moffitt Cancer Center & Research Institute [] You have full access to this article via your institution. Download PDF Related Articles * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] Building better CAR-T therapies * [d41586-023] The race to supercharge cancer-fighting T cells * [d41586-023] CRISPR cancer trial success paves the way for personalized treatments * [d41586-023] Cancer treatments boosted by immune-cell hacking Subjects * Immunology * Medical research * Biotechnology Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Live Expert Trainer-led workshops * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Professional development * Nature Careers * Nature Conferences Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2023 Springer Nature Limited